Endothelial Cells (ECs) Metabolism: A Valuable Piece to Disentangle Cancer Biology
- PMID: 32130698
- DOI: 10.1007/978-3-030-34025-4_8
Endothelial Cells (ECs) Metabolism: A Valuable Piece to Disentangle Cancer Biology
Abstract
Effective therapies to fight cancer should not be focused specifically on cancer cells, but it should consider the various components of the TME. Non-cancerous cells cooperate with cancer cells by sharing signaling and organic molecules, accounting for cancer progression. Most of the anti-angiogenic therapy clinically approved for the treatment of human diseases relies on targeting vascular endothelial growth factor (VEGF) signaling pathway. Unexpectedly and unfortunately, the results of anti-angiogenic therapies in the treatment of human diseases are not so effective, showing an insufficient efficacy and resistance.This chapter will give some insights on showing that targeting endothelial cell metabolism is a missing piece to revolutionize cancer therapy. Only recently endothelial cell (EC) metabolism has been granted as an important inducer of angiogenesis. Metabolic studies in EC demonstrated that targeting EC metabolism can be an alternative to overcome the failure of anti-angiogenic therapies. Hence, it is urgent to increase the knowledge on how ECs alter their metabolism during human diseases, in order to open new therapeutic perspectives in the treatment of pathophysiological angiogenesis, as in cancer.
Keywords: Angiogenesis; Cancer progression; Cancer therapy; Endothelial differentiation; Metabolic remodeling; Tumor microenvironment (TME).
Similar articles
-
Targeting endothelial cell metabolism in cancerous microenvironment: a new approach for anti-angiogenic therapy.Drug Metab Rev. 2022 Nov;54(4):386-400. doi: 10.1080/03602532.2022.2116033. Epub 2022 Aug 27. Drug Metab Rev. 2022. PMID: 36031813 Review.
-
Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.Int J Mol Sci. 2021 Apr 5;22(7):3765. doi: 10.3390/ijms22073765. Int J Mol Sci. 2021. PMID: 33916438 Free PMC article. Review.
-
Targeting fatty acid metabolism in cancer and endothelial cells.Crit Rev Oncol Hematol. 2016 Jan;97:15-21. doi: 10.1016/j.critrevonc.2015.10.011. Epub 2015 Nov 1. Crit Rev Oncol Hematol. 2016. PMID: 26558689 Review.
-
Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis.Pharmacol Ther. 2018 Nov;191:92-122. doi: 10.1016/j.pharmthera.2018.06.003. Epub 2018 Jun 29. Pharmacol Ther. 2018. PMID: 29909237 Review.
-
The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.Cytokine Growth Factor Rev. 2014 Aug;25(4):473-82. doi: 10.1016/j.cytogfr.2014.07.009. Epub 2014 Jul 23. Cytokine Growth Factor Rev. 2014. PMID: 25169850 Review.
Cited by
-
Metabolic Reprogramming of Vascular Endothelial Cells: Basic Research and Clinical Applications.Front Cell Dev Biol. 2021 Feb 18;9:626047. doi: 10.3389/fcell.2021.626047. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33681205 Free PMC article. Review.
-
Neutrophil extracellular traps promote angiogenesis in gastric cancer.Cell Commun Signal. 2023 Jul 21;21(1):176. doi: 10.1186/s12964-023-01196-z. Cell Commun Signal. 2023. PMID: 37480055 Free PMC article.
-
A Metabolic Signature to Monitor Endothelial Cell Differentiation, Activation, and Vascular Organization.Biomedicines. 2022 Sep 15;10(9):2293. doi: 10.3390/biomedicines10092293. Biomedicines. 2022. PMID: 36140393 Free PMC article.
-
Therapeutic efficacy of ECs Foxp1 targeting Hif1α-Hk2 glycolysis signal to restrict angiogenesis.Redox Biol. 2024 Sep;75:103281. doi: 10.1016/j.redox.2024.103281. Epub 2024 Jul 26. Redox Biol. 2024. PMID: 39083899 Free PMC article.
-
Molecular and Metabolic Reprogramming: Pulling the Strings Toward Tumor Metastasis.Front Oncol. 2021 Jun 3;11:656851. doi: 10.3389/fonc.2021.656851. eCollection 2021. Front Oncol. 2021. PMID: 34150624 Free PMC article. Review.
References
-
- Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464–478. https://doi.org/10.1038/nrm2183 - DOI - PubMed
-
- Amin DN, Hida K, Bielenberg DR, Klagsbrun M (2006) Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 66:2173–2180. https://doi.org/10.1158/0008-5472.CAN-05-3387 - DOI - PubMed
-
- Asthana A, Ramakrishnan P, Vicioso Y et al (2018) Hexosamine biosynthetic pathway inhibition leads to AML cell differentiation and cell death. Mol Cancer Ther 17:2226–2237. https://doi.org/10.1158/1535-7163.mct-18-0426 - DOI - PubMed - PMC
-
- Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410. https://doi.org/10.1038/nrc1093 - DOI - PubMed
-
- Blanco R, Gerhardt H (2013) VEGF and notch in tip and stalk cell selection. Cold Spring Harb Perspect Med 3:1–19 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical